Your account is not claimed yet. You can sign up with ORCID to claim your account.

Caitlyn T Solem (Caitlyn Solem)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 4

Top Venues

Patient related outcome measures

Cancer

ClinicoEconomics and outcomes research : CEOR

Blood

Pharmerit International

University of Illinois at Chicago (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Pharmerit International Aug 20o 2010

United States

Principal and Executive Director :: Real-world Evidence/ Data Analytics

Education History

University of Illinois at Chicago Aug 1o 2007 - Jun 30o 2010

United States

PHD :: Pharmacy Administration

Publications

Mahmoud Elsawy, Julio C Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D Rudzki, Saurabh Dahiya, Kathleen A Dorritie, Samantha M Jaglowski, John Radford, Judith Trotman, David Cunningham, Alejandro Martín García-Sancho, Dimitrios Tzachanis, Matthew L Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T Solem, Julia Thornton Snider, Paul Cheng, Christina To, Marie José Kersten
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood 140 (21) (2022)
Anuj Shah, Xinyi Ng, Ruchitbhai M Shah, Caitlyn T Solem, Ping Wang, Marko Obradovic
Psychometric Validation of the EQ-5D-3L in Patients with Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium avium Complex (MAC). Patient related outcome measures 12 (2021)
Caitlyn T Solem, Timothy J Bell, Youngmin Kwon, Joseph C Cappelleri, Courtney Johnson, Helen Bhattacharyya, Caroline J Hoang, Jorge E Cortes
A quality-adjusted survival time without symptoms or toxicities analysis of glasdegib plus low-dose cytarabine versus low-dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy. Cancer 126 (19) (2020)
Katharina Verleger, John R Penrod, Melinda Manley Daumont, Caitlyn T Solem, Linlin Luo, Cynthia Macahilig, Nadine Hertel
Costs and Cost Drivers Associated with Non-Small-Cell Lung Cancer Patients Who Received Two or More Lines of Therapy in Europe. ClinicoEconomics and outcomes research : CEOR 12 (2020)

Caitlyn T Solem.css-eqlu8i{font-size:small;padding-left:4px;} (Caitlyn Solem)

Publication Activity (10 Years)

Top Topics

Top Venues

Caitlyn T Solem (Caitlyn Solem)